Safety and tolerability of different total neoadjuvant therapy strategies in patients with locally advanced rectal cancer. First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB ...
A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...
Tumor lysis syndrome (esp. with high tumor burden); monitor renal function, fluid balance, electrolyte abnormalities (correct if occurs); discontinue if SCr rises or oliguria occurs. Monitor for ...
Secondary malignancies. Tumor lysis syndrome. Radiation sensitization/recall. Avoid extravasation. Hepatic impairment. Children (late cardiovascular dysfunction). Elderly. Embryo-fetal toxicity ...
The Business Research Company's Key Market Driver in Elitek or Fasturtec industry 2025: Rising Leukemia Prevalence Fuels Market Growth LONDON, GREATER LONDON, UNITED KINGDOM, January 25, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback